Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MDGL 
Madrigal Pharmaceuticals Inc (MDGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MDGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
15 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $461.43
1 Year Target Price $461.43
| 10 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19.37% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.74B USD | Price to earnings Ratio - | 1Y Target Price 461.43 |
Price to earnings Ratio - | 1Y Target Price 461.43 | ||
Volume (30-day avg) 15 | Beta -1.03 | 52 Weeks Range 200.63 - 439.00 | Updated Date 08/29/2025 |
52 Weeks Range 200.63 - 439.00 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.63 |
Earnings Date
Report Date 2025-08-05 | When - | Estimate -3.63 | Actual -1.9 |
Profitability
Profit Margin -54.68% | Operating Margin (TTM) -22.18% |
Management Effectiveness
Return on Assets (TTM) -18.31% | Return on Equity (TTM) -36.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9071013250 | Price to Sales(TTM) 18.9 |
Enterprise Value 9071013250 | Price to Sales(TTM) 18.9 | ||
Enterprise Value to Revenue 17.59 | Enterprise Value to EBITDA -8.32 | Shares Outstanding 22289000 | Shares Floating 10980906 |
Shares Outstanding 22289000 | Shares Floating 10980906 | ||
Percent Insiders 7.67 | Percent Institutions 107.81 |
Upturn AI SWOT
Madrigal Pharmaceuticals Inc
Company Overview
History and Background
Madrigal Pharmaceuticals, Inc. was founded in 2006. It is a biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH), now known as metabolic dysfunction-associated steatohepatitis (MASH), and other liver and cardiometabolic diseases.
Core Business Areas
- MASH/NASH Therapy Development: Development and commercialization of resmetirom, a THR-u03b2 selective agonist, for the treatment of MASH and related indications.
Leadership and Structure
Bill Sibold serves as the Chief Executive Officer. The company has a board of directors overseeing strategic direction and various executive teams managing operations.
Top Products and Market Share
Key Offerings
- Resmetirom (IZENAK): Resmetirom is a THR-u03b2 selective agonist for the treatment of MASH with liver fibrosis. IZENAK is the first approved treatment for MASH. Market share is nascent, as it is newly approved. Competitors include other companies developing MASH therapies, such as Viking Therapeutics, Akero Therapeutics, and 89bio.
Market Dynamics
Industry Overview
The NASH/MASH market is large and underserved, with a significant unmet medical need. There is increasing awareness of the disease and its progression to cirrhosis and liver cancer.
Positioning
Madrigal is positioned as a leader in the MASH therapeutics space with the first approved drug. Its competitive advantage lies in its first-mover advantage and the clinical data supporting resmetirom's efficacy.
Total Addressable Market (TAM)
The estimated TAM for NASH/MASH is billions of dollars. Madrigal is positioned to capture a significant portion of this market with IZENAK.
Upturn SWOT Analysis
Strengths
- First FDA-approved treatment for MASH
- Strong clinical data for resmetirom
- Experienced management team
- Strong financial position
Weaknesses
- Sole product dependency
- Reliance on regulatory approval and commercialization success
- Potential for competition from other therapies in development
Opportunities
- Expansion of resmetirom to other indications
- Partnerships and collaborations
- Increased awareness and diagnosis of MASH
- Geographic expansion
Threats
- Competition from other therapies
- Regulatory hurdles
- Pricing and reimbursement pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- GILD
- VKTX
- AKRO
Competitive Landscape
Madrigal currently has a first-mover advantage. Competition from Gilead, Viking, and Akero is likely to intensify in the coming years.
Growth Trajectory and Initiatives
Historical Growth: Prior to IZENAK approval, growth was primarily driven by clinical development progress. Future growth will be driven by resmetirom sales.
Future Projections: Analyst estimates project significant revenue growth over the next few years as resmetirom sales ramp up.
Recent Initiatives: FDA approval of resmetirom, commercial launch preparations, and expansion of clinical trials.
Summary
Madrigal Pharmaceuticals is a promising company due to its first-mover advantage with its NASH/MASH drug, IZENAK. The company has a robust financial background. However, Madrigal faces the challenge of commercializing IZENAK effectively, which will determine its market success. It needs to monitor competitor activities and continuously innovate to maintain its lead.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Press releases
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Madrigal Pharmaceuticals Inc
Exchange NASDAQ | Headquaters West Conshohocken, PA, United States | ||
IPO Launch date 2007-02-06 | CEO, President & Director Mr. William J. Sibold | ||
Sector Healthcare | Industry Biotechnology | Full time employees 528 | Website https://www.madrigalpharma.com |
Full time employees 528 | Website https://www.madrigalpharma.com | ||
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.